In the subcutaneous B16-FAP melanoma model, we found that FAP-IL2v significantly increased the tumor uptake of VAP-1-targeted [68Ga]Ga-DOTA-Siglec-9 7 days after baseline imaging, as measured by in vivo PET and ex vivo autoradiography methods. This evidence concerns the gene FAP and neoplasm.